

Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines

INTERIM GUIDANCE

1 JUNE 2021



World Health Organization



for every child



Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines

INTERIM GUIDANCE

1 JUNE 2021

This document is an update of the following publication:

Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines: interim guidance, 16 November 2020. World Health Organization (<https://apps.who.int/iris/handle/10665/336603>).

WHO/2019-nCoV/Vaccine_deployment/2021.1

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (<http://www.wipo.int/amc/en/mediation/rules/>)

Suggested citation. Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines: interim guidance, 1 June 2021. Geneva: World Health Organization; 2021 (WHO/2019-nCoV/Vaccine_deployment/2021.1). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements	vi
Abbreviations	viii
About this guide	ix
Target audience	x
Objectives of the guidance document	x
Organization and scope of the guidance document	x
Role of WHO SAGE on Immunization	xi
Key assumptions informing this guidance	xi
1. Introduction	1
1.1 Objectives of this chapter	2
1.2 Background	2
1.3 Coronavirus disease 2019	2
1.4 COVAX and COVID-19 vaccines	2
1.5 Considerations for COVID-19 vaccine introduction	4
1.6 Coordination with other health programmes or sectors	5
2. Regulatory preparedness	7
2.1 Objectives of this chapter	8
2.2 Establish emergency regulatory procedures	8
3. Planning, coordination and simulation exercises	12
3.1 Objectives of this chapter	13
3.2 Indemnity agreement and the COVAX no-fault compensation programme for AMC-eligible economies	13
3.3 Establish or adapt a COVID-19 vaccine deployment and vaccination coordination mechanism	14
3.4 Activate the national immunization technical advisory group	15
3.5 Establish a chain of reporting and management structure	16
3.6 Plan and conduct COVID-19 vaccine simulation exercises	18
4. Costing and funding: ensuring funds reach the point of delivery	19
4.1 Objectives of this chapter	20
4.2 Coordination with the COVID-19 Partners Platform	20
4.3 Estimate funding needs (costing)	21
4.4 Identify budget inputs and the responsible budgetary units	23
4.5 Assess and align costed plan within available resources	24
4.6 Assess need for changes in budgetary and public financial management processes	25
4.7 Funding options for mobilizing additional resources	25
5. Identification of target populations	27
5.1 Objectives of this chapter	28
5.2 Global allocation of COVID-19 vaccines	28
5.3 Define and identify target populations	29
5.4 Estimate size of targeted populations	31
5.5 Assure equity in distribution	32
5.6 Use of geospatial data and digital microplans for equitable access and delivery of COVID-19 vaccines	33

6. Vaccination delivery strategies	34
6.1 Objectives of this chapter	35
6.2 Vaccination strategies	35
7. Preparation of supply chain and management of health care waste	38
7.1 Objectives of this chapter	39
7.2 Prepare supply chain for vaccine deployment	39
7.3 Strengthen supply chain human resource capacity	40
7.4 Assess vaccine, logistics and cold chain capacity needs	40
7.5 Ensure supply chain system functionality	41
7.6 Manage and track vaccines effectively	42
7.7 Prepare for COVID-19 vaccine requiring ultra-cold chain (UCC) storage temperature	43
7.8 Manage reverse logistics	45
7.9 Manage health care waste	45
8. Human resource management and training	46
8.1 Objectives of this chapter	47
8.2 Identify human resources needs	47
8.3 Design and plan trainings	47
8.4 Decide on training methods	48
8.5 Enhance supportive supervision	49
8.6 Access key resources from WHO and other partners	49
8.7 Prepare for unique scenarios	50
9. Vaccine acceptance and uptake (demand)	51
9.1 Objectives of this chapter	52
9.2 Initiate demand planning	52
9.3 Understand and act on the drivers of vaccine acceptance and uptake	53
9.4 Develop an integrated demand approach	54
10. Vaccine safety monitoring, management of adverse events following immunization (AEFI) and injection safety	58
10.1 Objectives of this chapter	59
10.2 Address vaccine safety and pharmacovigilance challenges	59
10.3 Key vaccine pharmacovigilance considerations and the WHO COVID-19 vaccines safety surveillance manual	59
10.4 Ensure safe vaccination delivery	61
11. Immunization monitoring systems	63
11.1 Objectives of this chapter	64
11.2 Identify data needs and monitoring objectives	64
11.3 Define indicators to monitor progress	64
11.4 Design a system to record, report, analyse and use vaccination data	66
12. COVID-19 surveillance	70
12.1 Objectives of this chapter	71
12.2 Rationale, objectives and types of surveillance needed	71
12.3 Collect, report and use COVID-19 surveillance data	73
12.4 Address requested reporting requirements	73
13. Evaluation of COVID-19 vaccine introduction	74
13.1 Objectives of this chapter	75
13.2 Programmatic post-introduction evaluations of COVID-19 vaccines	75
13.3 Vaccine effectiveness and impact	76
13.4 Lessons learned	77

References.....	80
Annex 1: Sample template of national deployment and vaccination plan for COVID-19 vaccines... ..	87
Annex 2: COVID-19 epidemiology.....	91
Annex 3: COVID-19 vaccine-specific information with EUL or decision.....	93
Annex 4: Training decision-making and planning tool	95

Acknowledgements

Drafting editorial group

U.S. Centers for Disease Control and Prevention (CDC): Reena Doshi.

United Nations Children's Fund (UNICEF): Antoinette Ba-Nguz, Ulla Griffiths, Adama Sawadogo, Diane Summers, Ahmadu Yakubu.

Gavi, The Vaccine Alliance: Anissa Sidibe.

World Health Organization (WHO): Jhilmil Bahl, Madhava Balakrishnan, Alireza Khadem Broojerdi, Ado Bwaka, Maricel de Quiroz Castro, Diana Chang-Blanc, Shalini Desai, Eltayeb Elfakki, Daniel Feikin, Marta Gacic-Dobo, Ioana Ghiga, Jan Grevendonk, Santosh Gurung (Responsible Officer), Souleymane Kone, Gillian Mayers (consultant), Lisa Menning, Liudmila Mosina, Thomas O'Connell, Minal Patel, Alejandro Ramirez Gonzalez, Yuka Sumi, Nathalie Van de Maele, Jenny Walldorf.

Other contributors and reviewers

Bill & Melinda Gates Foundation: Kendall Krause, Emily Nickels, Jeff Pituch, Anna Rapp, Tove Ryman.

U.S. Centers for Disease Control (CDC): Neetu Abad, Brooke Aksnes, Sarah Bennett, Paul Chenoweth, Laura Conklin, Lauren Davidson, Terri Hyde, Eugene Lam, Carla Lee, Apophia Namageyo, Sarah Pallas, Abigail Shefer, Denise Traicoff, Kirsten Ward.

Clinton Health Access Initiative (CHAI): Sarah Snidal.

Coalition for Epidemic Preparedness Innovations (CEPI): Jim Robinson.

Gavi, The Vaccine Alliance: Laura Craw, Simon Duffield, Alex de Jonquieres, Susan Mackay, Zeenat Patel, Karan Sagar, Katja Schemionek, Stephen Sosler.

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Laetitia Bigger.

International Federation of Red Cross and Red Crescent Societies (IFRC): Katy Clarke, Frank Mahoney.

JSI Research & Training Institute, Inc.: Kate Bagshaw, Rebecca Fields, Enrique Paz, Lora Shimp.

Leeds Teaching Hospital NHS Trust: Anna Marie Ray.

MM Global Health (MMGH): Thomas Cherian, Carsten Mantel, Minzi Lam Meier.

United Nations Children's Fund (UNICEF): Bilal Ahmed, Khin Devi Aung, Niklas Danielsson, Michelle Dynes, Abu Obeida Eltayeb, Patrick Gaparayi, Eric Laurent, Yalda Momeni, Naureen Navqi, Rocco Panciera, Deepa Pokharel, Michelle Seidel, Angus Thomson, Claudia Vivas.

World Health Organization (WHO): Claudia Alfonso, Benedetta Allegranzi, Ananda Amarasinghe, Jotheeswaran Amuthavalli Thiyagarajan, April Baller, Nyambat Batmunkh, Adwoa Bentsi-Enchill, Paul Bloem, Daniel Brigden, Aleksandra Caric, Nathalie Chenavard, Giorgio Cometto, Frederik Copper, Cory Couillard, Peter Cowley, Natasha Crowcroft, Hemanthi Dassanayake, Ayesha de Costa, Elsa Derobert, Theresa Diaz, Leilia Dore, Linda Doull, Kamal Fahmy, Olga Fradkina, Carole Fry, Shoshanna Goldin, Tracey Goodman, Zee A Han, Qamrul Hasan, Louise Henaff, Karene Hoi Ting Yeung, Joachim Hombach, Raymond Hutubessy, Kamal Ait-Ikhlef, Ivan Ivanov, Alya Jaafar Dabbagh, Michael Jendryke, Catherine Kane, Kanokporn Kaojaroen, Joseph Kutzin, Jack Lewis, Ann Lindstrand, Anne Hélène Mazur, Anne Moen, Margaret Montgomery, Jason Mwenda, Matthew Neilson, Laura Nic Lochlainn, Shanthi Pal, Kate O'Brien, Katherin O'Neill, Razieh Ostad Ali Dehaghi, Roberta Pastore, William Perea Caro Augusto, Ute Pieper, Ave

Pold, Mohamed Refaat, Alba Maria Roper, Ravi Shankar Santhana Gopala Krishnan, Santino Severoni, Angela Shen, Stephanie Shendale, Jinho Shin, Hiiti Baran Sillo, Alice Simniceanu, Agnes Soucat, Susan Sparkes, Christoph Steffen, Shamsuzzoha Syed, Carol Tevi-Benissan, Florian Tille, Marie Valentine, Reinhilde Van De Weerd, Alba Vilajeliu, Mufti Zubair Wadood, Susan Wang, Annelies Wilder-Smith, David Wood, Yap Wei Aun, Nasir Yusuf, Simona Zipursky.

The World Bank: Sulzhan Bali, Clementine Murer, Michael Kent Ranson.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23847

